董事介绍

姓名 性别 职位 年龄 薪酬 截止日期
Leon O. Moulder, Jr. Director,President and Chief Operating Officer 58 547.94万(USD) 2016-04-08
Mary Lynne Hedley Director,Chief Executive Officer 53 459.86万(USD) 2016-04-08
Garry A. Nicholson Director 61 94.21万(USD) 2016-04-08
David M. Mott Director 50 42.31万(USD) 2016-04-08
Lawrence M. Alleva Director 66 40.56万(USD) 2016-04-08
Arnold L. Oronsky Director 76 40.16万(USD) 2016-04-08
Earl M. Collier, Jr. Director 68 40.06万(USD) 2016-04-08
Beth Seidenberg Director 59 39.81万(USD) 2016-04-08
James O. Armitage Director 69 39.56万(USD) 2016-04-08
Kavita Patel. Director 42 -- 2016-04-08

高管介绍

姓名 性别 职位 年龄 薪酬 截止日期
Jeffrey H. Hanke Executive Vice President, Research and Development, and Chief Scientific Officer 59 648.34万(USD) 2016-04-08
Leon O. Moulder, Jr. Director,President and Chief Operating Officer 58 547.94万(USD) 2016-04-08
Mary Lynne Hedley Director,Chief Executive Officer 53 459.86万(USD) 2016-04-08
Grant C. Bogle Senior Vice President and Chief Commercial Officer 58 304.48万(USD) 2016-04-08
Timothy R. Pearson Executive Vice President and Chief Financial Officer 48 235.87万(USD) 2016-04-08
Joseph L. Farmer Senior Vice President, General Counsel and Secretary 44 -- 2016-04-08
Martin H. Huber Senior Vice President and Chief Medical Officer 56 -- 2016-04-08

董事简历

中文 |  英文 |  中英对照
Leon O. Moulder, Jr.
Leon O. Moulder, Jr.自2010年3月共同创办公司担任首席执行官,并成为我们的董事会成员,从2009年4月至2010年1月Moulder先生担任Abraxis生物科技公司董事会副主席、总裁兼首席执行官,这是一家生物技术公司,并担任其全资运营子公司,Abraxis生物科技有限责任公司和Abraxis公司肿瘤事业部的总裁兼首席执行官。在此之前,从2008年1月至2009年1月Moulder先生担任 Eisai北美公司的副主席,直到2008年1月被制药公司MGI PHARMA公司收购。Moulder先生从2003年5月到2008年1月担任MGI PHARMA公司总裁兼首席执行官,并且是董事会成员。Moulder先生于1999年9月加入MGI PHARMA,担任执行副总裁并于2002年5月晋升为总裁首席运营官。Moulder先生获得坦普尔大学(Temple University)药剂学学士学位和芝加哥大学(University of Chicago)工商管理硕士学位。Moulder先生目前担任Trevena公司董事会主席,该公司全国证券交易商自动报价系统协会代码为TRVN(NASDAQ: TRVN),并作为Cubist Pharmaceuticals公司的董事,该公司全国证券交易商自动报价系统协会代码为CBST(NASDAQ: CBST),这两者都是生物制药企业,并作为坦普尔大学(Temple University)的信托人。
Leon O. Moulder, Jr. has served as Chief Executive Officer and as a member of our board of directors since co-founding the Company in March 2010. From April 2009 to January 2010 Mr. Moulder served as vice chairman of the board of directors and president and chief executive officer of Abraxis BioScience, Inc., a biotechnology company. Before that, Mr. Moulder served as vice chairman of Eisai Corporation of North America, from January 2008 until January 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc., a pharmaceutical company, in January 2008. Mr. Moulder served as president and chief executive officer and as member of the board of directors of MGI PHARMA, Inc. from May 2003 through January 2008. Mr. Moulder joined MGI PHARMA, Inc. in September 1999 as executive vice president and was promoted to president and chief operating officer in May 2002. Mr. Moulder earned a bachelor of science degree in pharmacy from Temple University and a master of business administration degree from the University of Chicago. Mr. Moulder currently serves as chairman of the board of directors of Trevena, Inc. NASDAQ: TRVN, as a trustee of Temple University, and is on the board of the Fox Chase Cancer Center. Mr. Moulder also served as a director of Cubist Pharmaceuticals, Inc. through the sale of the company in 2015.
Leon O. Moulder, Jr. has served as Chief Executive Officer and as a member of our board of directors since co-founding the Company in March 2010. From April 2009 to January 2010 Mr. Moulder served as vice chairman of the board of directors and president and chief executive officer of Abraxis BioScience, Inc., a biotechnology company. Before that, Mr. Moulder served as vice chairman of Eisai Corporation of North America, from January 2008 until January 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc., a pharmaceutical company, in January 2008. Mr. Moulder served as president and chief executive officer and as member of the board of directors of MGI PHARMA, Inc. from May 2003 through January 2008. Mr. Moulder joined MGI PHARMA, Inc. in September 1999 as executive vice president and was promoted to president and chief operating officer in May 2002. Mr. Moulder earned a bachelor of science degree in pharmacy from Temple University and a master of business administration degree from the University of Chicago. Mr. Moulder currently serves as chairman of the board of directors of Trevena, Inc. NASDAQ: TRVN, as a trustee of Temple University, and is on the board of the Fox Chase Cancer Center. Mr. Moulder also served as a director of Cubist Pharmaceuticals, Inc. through the sale of the company in 2015.

Leon O. Moulder, Jr.自2010年3月共同创办公司担任首席执行官,并成为我们的董事会成员,从2009年4月至2010年1月Moulder先生担任Abraxis生物科技公司董事会副主席、总裁兼首席执行官,这是一家生物技术公司,并担任其全资运营子公司,Abraxis生物科技有限责任公司和Abraxis公司肿瘤事业部的总裁兼首席执行官。在此之前,从2008年1月至2009年1月Moulder先生担任 Eisai北美公司的副主席,直到2008年1月被制药公司MGI PHARMA公司收购。Moulder先生从2003年5月到2008年1月担任MGI PHARMA公司总裁兼首席执行官,并且是董事会成员。Moulder先生于1999年9月加入MGI PHARMA,担任执行副总裁并于2002年5月晋升为总裁首席运营官。Moulder先生获得坦普尔大学(Temple University)药剂学学士学位和芝加哥大学(University of Chicago)工商管理硕士学位。Moulder先生目前担任Trevena公司董事会主席,该公司全国证券交易商自动报价系统协会代码为TRVN(NASDAQ: TRVN),并作为Cubist Pharmaceuticals公司的董事,该公司全国证券交易商自动报价系统协会代码为CBST(NASDAQ: CBST),这两者都是生物制药企业,并作为坦普尔大学(Temple University)的信托人。

Mary Lynne Hedley
Mary Lynne Hedley自2010年3月共同创办公司担任公司总裁兼首席科学官,并是我们的董事会成员,从2009年7月至2010年2月Hedley博士担任Abraxis生物科学公司的运营部执行副总裁兼首席科学官,这是一家生物技术公司。从2008年1月至2009年7月Hedley博士担任北美卫材公司(Eisai Corporation of North America)的执行副总裁,该公司于2008年1月被MGI PHARMA公司收购。Hedley博士从2004年到2008年1月它收购Eisai,曾在MGI PHARMA不同的岗位任职,最近担任执行副总裁兼首席科学官。在此之前,Hedley博士于2004年共同创办Zycos,博士担任ZYCOS公司的总裁兼首席执行官,是一家生物技术公司,该公司被MGI制药公司收购。Hedley获得哈佛大学(Harvard University)两个连续的博士后奖学金。Hedley博士获得普渡大学(Purdue University)微生物学士学位和德克萨斯大学西南医学中心(the University of Texas, Southwestern Medical Center)免疫博士学位。
Mary Lynne Hedley has served as our President and as a member of our board of directors since co-founding the Company in March 2010. She also served in the role of Chief Scientific Officer from the Company's founding until the board of directors appointed her to the role of Chief Operating Officer effective July 24 2014. From July 2009 to February 2010 Dr. Hedley served as executive vice president of operations and chief scientific officer of Abraxis BioScience, Inc., a biotechnology company. Dr. Hedley served as executive vice president of Eisai Corporation of North America from January 2008 until July 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc. in January 2008. Dr. Hedley served in various positions at MGI PHARMA, Inc. from 2004 through its acquisition in January 2008 most recently as executive vice president and chief scientific officer. Prior to that, Dr. Hedley co-founded and served as the president and chief executive officer of ZYCOS, Inc., a biotechnology company, which was acquired by MGI PHARMA, Inc. in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University. Dr. Hedley earned a bachelor of science degree in microbiology from Purdue University and degree in immunology from the University of Texas, Southwestern Medical Center. Dr. Hedley currently serves as a director of Youville Place, Inc. She also served on the board of Receptos, Inc. prior to its acquisition by Celgene Corp. in August 2015.
Mary Lynne Hedley has served as our President and as a member of our board of directors since co-founding the Company in March 2010. She also served in the role of Chief Scientific Officer from the Company's founding until the board of directors appointed her to the role of Chief Operating Officer effective July 24 2014. From July 2009 to February 2010 Dr. Hedley served as executive vice president of operations and chief scientific officer of Abraxis BioScience, Inc., a biotechnology company. Dr. Hedley served as executive vice president of Eisai Corporation of North America from January 2008 until July 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc. in January 2008. Dr. Hedley served in various positions at MGI PHARMA, Inc. from 2004 through its acquisition in January 2008 most recently as executive vice president and chief scientific officer. Prior to that, Dr. Hedley co-founded and served as the president and chief executive officer of ZYCOS, Inc., a biotechnology company, which was acquired by MGI PHARMA, Inc. in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University. Dr. Hedley earned a bachelor of science degree in microbiology from Purdue University and degree in immunology from the University of Texas, Southwestern Medical Center. Dr. Hedley currently serves as a director of Youville Place, Inc. She also served on the board of Receptos, Inc. prior to its acquisition by Celgene Corp. in August 2015.

Mary Lynne Hedley自2010年3月共同创办公司担任公司总裁兼首席科学官,并是我们的董事会成员,从2009年7月至2010年2月Hedley博士担任Abraxis生物科学公司的运营部执行副总裁兼首席科学官,这是一家生物技术公司。从2008年1月至2009年7月Hedley博士担任北美卫材公司(Eisai Corporation of North America)的执行副总裁,该公司于2008年1月被MGI PHARMA公司收购。Hedley博士从2004年到2008年1月它收购Eisai,曾在MGI PHARMA不同的岗位任职,最近担任执行副总裁兼首席科学官。在此之前,Hedley博士于2004年共同创办Zycos,博士担任ZYCOS公司的总裁兼首席执行官,是一家生物技术公司,该公司被MGI制药公司收购。Hedley获得哈佛大学(Harvard University)两个连续的博士后奖学金。Hedley博士获得普渡大学(Purdue University)微生物学士学位和德克萨斯大学西南医学中心(the University of Texas, Southwestern Medical Center)免疫博士学位。

Garry A. Nicholson
暂无中文简介
Garry A. Nicholson has served on our board of directors since May 2015. Mr. Nicholson has served as President, Chief Executive Officer and a member of the board of directors of XTuit Pharmaceuticals, Inc., a biopharmaceutical company, since September 2015. Prior to that, he served as President, Pfizer Oncology, from May 2008 until March 2015. He joined Pfizer, Inc. "Pfizer", as the first leader of its global, dedicated oncology business, with direct responsibility for business strategy and operations. He was responsible for clinical development for both early and late stage medicines, for all oncology sales and marketing organizations globally, and for licensing, acquisitions, and the oncology therapeutic area strategy. In addition to his oncology role, he was a member of the Portfolio Strategy and Investment Committee, the governance body with the oversight responsibility for Pfizer research and development. He also served as a member of the Pfizer Foundation board of directors. Prior to joining Pfizer, Mr. Nicholson worked at Eli Lilly and Company ("Lilly"), in a number of leadership roles, including sales management, marketing, human resources, and as the pharmaceutical commercial leader in Italy. He assumed the responsibility for the sales and marketing of Lilly's cancer products in the U.S. in 1996 and subsequently managed oncology drug development. Mr. Nicholson earned a bachelor of science degree in pharmacy from the University of North Carolina, Chapel Hill, and a master of business administration degree from the University of South Carolina, Columbia. Mr. Nicholson has also served on the board of directors of SQZ Biotech, a cell therapy company, since December 2015.
Garry A. Nicholson has served on our board of directors since May 2015. Mr. Nicholson has served as President, Chief Executive Officer and a member of the board of directors of XTuit Pharmaceuticals, Inc., a biopharmaceutical company, since September 2015. Prior to that, he served as President, Pfizer Oncology, from May 2008 until March 2015. He joined Pfizer, Inc. "Pfizer", as the first leader of its global, dedicated oncology business, with direct responsibility for business strategy and operations. He was responsible for clinical development for both early and late stage medicines, for all oncology sales and marketing organizations globally, and for licensing, acquisitions, and the oncology therapeutic area strategy. In addition to his oncology role, he was a member of the Portfolio Strategy and Investment Committee, the governance body with the oversight responsibility for Pfizer research and development. He also served as a member of the Pfizer Foundation board of directors. Prior to joining Pfizer, Mr. Nicholson worked at Eli Lilly and Company ("Lilly"), in a number of leadership roles, including sales management, marketing, human resources, and as the pharmaceutical commercial leader in Italy. He assumed the responsibility for the sales and marketing of Lilly's cancer products in the U.S. in 1996 and subsequently managed oncology drug development. Mr. Nicholson earned a bachelor of science degree in pharmacy from the University of North Carolina, Chapel Hill, and a master of business administration degree from the University of South Carolina, Columbia. Mr. Nicholson has also served on the board of directors of SQZ Biotech, a cell therapy company, since December 2015.

暂无中文简介
David M. Mott
自2010年5月David M. Mott作为董事会成员,并于2011年7月成为董事会主席。自2008年9月,他领导医疗保健投资实践,Mott先生曾担任New Enterprise Associates的普通合伙人,这是一家投资公司,专注于风险投资和成长股权投资。从1992年至2008年Mott先生曾在MedImmune有限公司工作,这是一家生物技术公司也是AstraZeneca Plc公司,该公司在纽约证券交易所代码为AZN(NYSE:AZN)的子公司,从2000年10月至2008年7月他在任期内担任多种职务,包括财务总监,总裁兼首席运营官,最近担任首席执行官,在此期间,Mott先生从2007年6月至2008年7月在AstraZeneca Plc公司任职执行副总裁,该公司于2007年6月被MedImmune有限公司收购。加盟MedImmune有限公司之前,Mott先生在Smith Barney, Harris Upham公司担任医疗保健银行投资副总裁职位。Mott先生获得了达特茅斯学院(Dartmouth College)文学士学位。Mott先生还担任Prosensa控股公司,该公司全国证券交易商自动报价系统协会代码为RNA(NASDAQ:RNA)的董事长,并担任Epizyme公司,该公司全国证券交易商自动报价系统协会代码为EPZM(NASDAQ:EPZM)的董事会成员,还担任多个私人持有的生命科学公司董事会成员。
David M. Mott has served as a director since December 2009 and as Chairman of the board since April 2016. Mr. Mott has served as a general partner of New Enterprise Associates, Inc., an investment firm focused on venture capital and growth equity investments and a holder of more than 5 of our voting securities, since September 2008 where he leads the healthcare investing practice. From 1992 until 2008 Mr. Mott worked at MedImmune, Inc., or MedImmune, a biotechnology company and subsidiary of AstraZeneca Plc, or AstraZeneca, and served in numerous roles during his tenure, including most recently as Chief Executive Officer from October 2000 to July 2008. During that time, Mr. Mott also served as Executive Vice President of AstraZeneca from June 2007 to July 2008 following AstraZeneca’s acquisition of MedImmune in June 2007. Prior to joining MedImmune, Mr. Mott was a Vice President in the healthcare investment banking group at Smith Barney, Harris Upham & Co. Inc. Mr. Mott also serves as the Chairman of the board of directors of both TESARO and Ardelyx, Inc., and serves on the board of directors of Adaptimmune Therapeutics plc. Mr. Mott received a B.A. from Dartmouth College.
David M. Mott has served as a director since December 2009 and as Chairman of the board since April 2016. Mr. Mott has served as a general partner of New Enterprise Associates, Inc., an investment firm focused on venture capital and growth equity investments and a holder of more than 5 of our voting securities, since September 2008 where he leads the healthcare investing practice. From 1992 until 2008 Mr. Mott worked at MedImmune, Inc., or MedImmune, a biotechnology company and subsidiary of AstraZeneca Plc, or AstraZeneca, and served in numerous roles during his tenure, including most recently as Chief Executive Officer from October 2000 to July 2008. During that time, Mr. Mott also served as Executive Vice President of AstraZeneca from June 2007 to July 2008 following AstraZeneca’s acquisition of MedImmune in June 2007. Prior to joining MedImmune, Mr. Mott was a Vice President in the healthcare investment banking group at Smith Barney, Harris Upham & Co. Inc. Mr. Mott also serves as the Chairman of the board of directors of both TESARO and Ardelyx, Inc., and serves on the board of directors of Adaptimmune Therapeutics plc. Mr. Mott received a B.A. from Dartmouth College.

自2010年5月David M. Mott作为董事会成员,并于2011年7月成为董事会主席。自2008年9月,他领导医疗保健投资实践,Mott先生曾担任New Enterprise Associates的普通合伙人,这是一家投资公司,专注于风险投资和成长股权投资。从1992年至2008年Mott先生曾在MedImmune有限公司工作,这是一家生物技术公司也是AstraZeneca Plc公司,该公司在纽约证券交易所代码为AZN(NYSE:AZN)的子公司,从2000年10月至2008年7月他在任期内担任多种职务,包括财务总监,总裁兼首席运营官,最近担任首席执行官,在此期间,Mott先生从2007年6月至2008年7月在AstraZeneca Plc公司任职执行副总裁,该公司于2007年6月被MedImmune有限公司收购。加盟MedImmune有限公司之前,Mott先生在Smith Barney, Harris Upham公司担任医疗保健银行投资副总裁职位。Mott先生获得了达特茅斯学院(Dartmouth College)文学士学位。Mott先生还担任Prosensa控股公司,该公司全国证券交易商自动报价系统协会代码为RNA(NASDAQ:RNA)的董事长,并担任Epizyme公司,该公司全国证券交易商自动报价系统协会代码为EPZM(NASDAQ:EPZM)的董事会成员,还担任多个私人持有的生命科学公司董事会成员。

Lawrence M. Alleva
Lawrence M. Alleva,于2012年3月被任命为公司董事会成员。Alleva先生目前已退休。在他2010年6月退休之前,Alleva先生受雇于 PricewaterhouseCoopers LLP, or PwC39年,在第28年的时候成为该事务所的合伙人。 Alleva先生服务的客户主要在技术领域,包括制药和生物技术公司。此外,他曾在各种办事处和地区实践领导职务,最近从2006年直到他退休担任普华永道(PwC)的道德与规范的领导担保人。 Alleva先生是一名不活跃的注册会计师。 Alleva先生获得伊萨卡学院(Ithaca College)会计学的学士学位并参加哥伦比亚大学(Columbia University)高级工商管理硕士(非学位)项目。 Alleva先生还担任GlobalLogic公司和Bright Horizons Family Solutions公司的董事。
Lawrence M. Alleva joined our board in July 2014. Prior to his retirement in June 2010 Mr. Alleva worked with PricewaterhouseCoopers LLP, or PwC, for 39 years, 28 of which as a partner with the firm. Mr. Alleva served clients primarily in the technology sector, including numerous pharmaceutical and biotechnology companies. Additionally, he served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader Assurance for PwC from 2006 until his retirement. Mr. Alleva is a Certified Public Accountant (inactive). Mr. Alleva received a Bachelor of Science degree from Ithaca College (magna cum laude) and attended Columbia University's Executive MBA program. Mr. Alleva also serves as a director for public companies Tesaro Inc. and Bright Horizons Family Solutions, and previously served on the board of GlobalLogic Inc.
Lawrence M. Alleva joined our board in July 2014. Prior to his retirement in June 2010 Mr. Alleva worked with PricewaterhouseCoopers LLP, or PwC, for 39 years, 28 of which as a partner with the firm. Mr. Alleva served clients primarily in the technology sector, including numerous pharmaceutical and biotechnology companies. Additionally, he served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader Assurance for PwC from 2006 until his retirement. Mr. Alleva is a Certified Public Accountant (inactive). Mr. Alleva received a Bachelor of Science degree from Ithaca College (magna cum laude) and attended Columbia University's Executive MBA program. Mr. Alleva also serves as a director for public companies Tesaro Inc. and Bright Horizons Family Solutions, and previously served on the board of GlobalLogic Inc.

Lawrence M. Alleva,于2012年3月被任命为公司董事会成员。Alleva先生目前已退休。在他2010年6月退休之前,Alleva先生受雇于 PricewaterhouseCoopers LLP, or PwC39年,在第28年的时候成为该事务所的合伙人。 Alleva先生服务的客户主要在技术领域,包括制药和生物技术公司。此外,他曾在各种办事处和地区实践领导职务,最近从2006年直到他退休担任普华永道(PwC)的道德与规范的领导担保人。 Alleva先生是一名不活跃的注册会计师。 Alleva先生获得伊萨卡学院(Ithaca College)会计学的学士学位并参加哥伦比亚大学(Columbia University)高级工商管理硕士(非学位)项目。 Alleva先生还担任GlobalLogic公司和Bright Horizons Family Solutions公司的董事。

Arnold L. Oronsky
Arnold L. Oronsky, 在2011年6月以来一直担任我们的董事会董事。他已经成为InterWest Partners(一家风险资本公司,自1994年以来主要关注生命科学)的普通合伙人。他还担任Johns Hopkins Medical School高级讲师。加入IInterWest Partners之前,他担任 American Cyanamid Company副董事,负责Lederle实验室部门研究。他拥有哥伦比亚大学(Columbia University)免疫学博士学位和纽约大学(New York University)文学学士学位。他担任 Dynavax Technologies NASDAQ: DVAX(一家生物技术公司)的董事会主席, MacroGenics, Inc.(一家生物技术公司)董事会董事。此外,他是一些私人的生命科学公司董事会董事。
Arnold L. Oronsky has served as a member of our board of directors since November 2003. Dr. Oronsky has been a general partner at InterWest Venture Management Co., a venture capital firm, since 1994. Prior to joining InterWest, Dr. Oronsky was vice president for discovery research at Lederle Laboratories, a division of American Cyanamid Company focused on the production of vaccines. Dr. Oronsky holds a Ph.D. in Immunology from Columbia University and has published over 125 scientific articles. He also serves as a Senior Lecturer in the Department of Medicine at Johns Hopkins Medical School. Dr. Oronsky serves as the chairman of the board of directors of Dynavax Technologies Corporation, a biopharmaceutical company, as well as on the board of directors TESARO, Inc., an oncology-focused biopharmaceutical company. Dr. Oronsky also served on the boards of directors of the biopharmaceutical companies, MacroGenics, Inc., from 2000 to 2014 Metabasis Therapeutics, Inc., from 2000 to 2010 and Anesiva, Inc., from 2005 to 2010. Anesiva filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Northern District of California in January 2010.
Arnold L. Oronsky has served as a member of our board of directors since November 2003. Dr. Oronsky has been a general partner at InterWest Venture Management Co., a venture capital firm, since 1994. Prior to joining InterWest, Dr. Oronsky was vice president for discovery research at Lederle Laboratories, a division of American Cyanamid Company focused on the production of vaccines. Dr. Oronsky holds a Ph.D. in Immunology from Columbia University and has published over 125 scientific articles. He also serves as a Senior Lecturer in the Department of Medicine at Johns Hopkins Medical School. Dr. Oronsky serves as the chairman of the board of directors of Dynavax Technologies Corporation, a biopharmaceutical company, as well as on the board of directors TESARO, Inc., an oncology-focused biopharmaceutical company. Dr. Oronsky also served on the boards of directors of the biopharmaceutical companies, MacroGenics, Inc., from 2000 to 2014 Metabasis Therapeutics, Inc., from 2000 to 2010 and Anesiva, Inc., from 2005 to 2010. Anesiva filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Northern District of California in January 2010.

Arnold L. Oronsky, 在2011年6月以来一直担任我们的董事会董事。他已经成为InterWest Partners(一家风险资本公司,自1994年以来主要关注生命科学)的普通合伙人。他还担任Johns Hopkins Medical School高级讲师。加入IInterWest Partners之前,他担任 American Cyanamid Company副董事,负责Lederle实验室部门研究。他拥有哥伦比亚大学(Columbia University)免疫学博士学位和纽约大学(New York University)文学学士学位。他担任 Dynavax Technologies NASDAQ: DVAX(一家生物技术公司)的董事会主席, MacroGenics, Inc.(一家生物技术公司)董事会董事。此外,他是一些私人的生命科学公司董事会董事。

Earl M. Collier, Jr.
Earl M. Collier, Jr.,2011年加入Capricor, Inc董事会,是公司提名委员会及治理委员会成员。从2010年到2014年,他担任480 Biomedical(一家医疗设备公司,开发的产品用于外周动脉疾病的治疗)首席执行官和Arsenal Medical, Inc.(一家医疗设备公司)执行主席。Collier先生曾担任Genzyme Corporation(一家生物技术公司,2011年被Sanofi 以201亿美元收购)执行副总裁。他在GenzymeCorporation任职期间,负责建设经营生物外科事务和监督公司肿瘤、多发性硬化症和其他免疫系统疾病的进展。他领导了Genzyme一些重大收购工作和MG Biotherapeutics(Genzyme与Medtronic Inc的合资公司,专注于心肌细胞治疗)的成立。他还担任Vitas Healthcare(一家临终关怀机构,是位于华盛顿的法律公司Hogan and Hartson的合作伙伴)总裁和美国健康与人类服务部卫生保健财政管理局(现称CMS)副局长。他是牛顿韦尔斯利医院董事会主席、医疗系统的合作伙伴董事会成员和合作医疗创新顾问委员会主席。从2006年到2009年,Collier先生担任上市公司Decode Genetics Inc. (即DGI Resolution, Inc,是一家生物制药公司)董事长。他目前担任Tesaro, Inc.(一个公开上市的生物制药公司)董事会成员,和Transmedics(私人医疗器械公司)董事会成员。他在耶鲁大学获得了文学学士学位,在弗吉尼亚大学获得了法学学位。
Earl M. Collier, Jr. joined the Capricor, Inc. Board of Directors in 2011 and is a member of the Company’s Nominating and Corporate Governance Committee. From 2010-2014 he served as the Chief Executive Officer of 480 Biomedical, a medical device company developing products used in the treatment of peripheral artery disease, and the executive chairman of Arsenal Medical, Inc., a medical device company. Mr. Collier was formerly Executive Vice President at Genzyme Corporation, a biotechnology company acquired by Sanofi for $20.1 billion in 2011. During his tenure at Genzyme, Mr. Collier was responsible for building the biosurgery business and overseeing the company’s efforts in oncology, multiple sclerosis and other immune disorders. He led some of Genzyme’s significant acquisitions and the formation of MG Biotherapeutics, Genzyme’s joint venture with Medtronic Inc., which focused on cardiac cell therapy. Mr. Collier also served as President of Vitas Healthcare, a hospice provider, as a partner at the Washington, DC-based law firm of Hogan and Hartson and as Deputy Administrator of the Health Care Finance Administration now CMS in the U.S. Department of Health & Human Services. He is also chairman of the board of trustees for the Newton-Wellesley Hospital, serves on the board of Partners HealthCare System and as Chair of the Innovation Advisory Board of Partners HealthCare. From 2006 to 2009 Mr. Collier served as a director of publicly-traded Decode Genetics Inc. (DGI Resolution, Inc.), a biopharmaceutical company, and he currently serves on the board of directors of Tesaro, Inc., a publicly-traded biopharmaceutical company, and on the board of directors of Transmedics, a private medical device company. Mr. Collier earned a Bachelor of Arts degree at Yale University and received a law degree from the University of Virginia Law School.
Earl M. Collier, Jr. joined the Capricor, Inc. Board of Directors in 2011 and is a member of the Company’s Nominating and Corporate Governance Committee. From 2010-2014 he served as the Chief Executive Officer of 480 Biomedical, a medical device company developing products used in the treatment of peripheral artery disease, and the executive chairman of Arsenal Medical, Inc., a medical device company. Mr. Collier was formerly Executive Vice President at Genzyme Corporation, a biotechnology company acquired by Sanofi for $20.1 billion in 2011. During his tenure at Genzyme, Mr. Collier was responsible for building the biosurgery business and overseeing the company’s efforts in oncology, multiple sclerosis and other immune disorders. He led some of Genzyme’s significant acquisitions and the formation of MG Biotherapeutics, Genzyme’s joint venture with Medtronic Inc., which focused on cardiac cell therapy. Mr. Collier also served as President of Vitas Healthcare, a hospice provider, as a partner at the Washington, DC-based law firm of Hogan and Hartson and as Deputy Administrator of the Health Care Finance Administration now CMS in the U.S. Department of Health & Human Services. He is also chairman of the board of trustees for the Newton-Wellesley Hospital, serves on the board of Partners HealthCare System and as Chair of the Innovation Advisory Board of Partners HealthCare. From 2006 to 2009 Mr. Collier served as a director of publicly-traded Decode Genetics Inc. (DGI Resolution, Inc.), a biopharmaceutical company, and he currently serves on the board of directors of Tesaro, Inc., a publicly-traded biopharmaceutical company, and on the board of directors of Transmedics, a private medical device company. Mr. Collier earned a Bachelor of Arts degree at Yale University and received a law degree from the University of Virginia Law School.

Earl M. Collier, Jr.,2011年加入Capricor, Inc董事会,是公司提名委员会及治理委员会成员。从2010年到2014年,他担任480 Biomedical(一家医疗设备公司,开发的产品用于外周动脉疾病的治疗)首席执行官和Arsenal Medical, Inc.(一家医疗设备公司)执行主席。Collier先生曾担任Genzyme Corporation(一家生物技术公司,2011年被Sanofi 以201亿美元收购)执行副总裁。他在GenzymeCorporation任职期间,负责建设经营生物外科事务和监督公司肿瘤、多发性硬化症和其他免疫系统疾病的进展。他领导了Genzyme一些重大收购工作和MG Biotherapeutics(Genzyme与Medtronic Inc的合资公司,专注于心肌细胞治疗)的成立。他还担任Vitas Healthcare(一家临终关怀机构,是位于华盛顿的法律公司Hogan and Hartson的合作伙伴)总裁和美国健康与人类服务部卫生保健财政管理局(现称CMS)副局长。他是牛顿韦尔斯利医院董事会主席、医疗系统的合作伙伴董事会成员和合作医疗创新顾问委员会主席。从2006年到2009年,Collier先生担任上市公司Decode Genetics Inc. (即DGI Resolution, Inc,是一家生物制药公司)董事长。他目前担任Tesaro, Inc.(一个公开上市的生物制药公司)董事会成员,和Transmedics(私人医疗器械公司)董事会成员。他在耶鲁大学获得了文学学士学位,在弗吉尼亚大学获得了法学学位。

Beth Seidenberg
Beth Seidenberg自2011年6月担任公司董事会成员,自2005年5月,Seidenberg博士是凯鹏华拜耳公司(Kleiner Perkins Caufield & Byers)的合伙人,这是一家风险投资公司,在那里她主要集中于生命科学投资。Seidenberg博士曾任安进公司(Amgen, Inc)的高级副总裁兼全球发展负责人和首席医疗官,该公司在全国证券交易商自动报价系统协会代码为AMGN(NASDAQ:AMGN),是一家生物技术公司。此外,Seidenberg博士在一家生物制药公司Bristol Myers Squibb公司,该公司在纽约证券交易所代码为AMGN(NYSE:BMY)以及医疗保健公司默克制药公司(Merck & Co., Inc),该公司在纽约证券交易所代码为MRK(NYSE:MRK),任职研究和开发的高级管理人员。Seidenberg博士获迈阿密医药大学(University of Miami School of Medicine)医学士学位和巴纳德学院(Barnard College)理学学士学位,并完成了约翰·霍普金斯大学(Johns Hopkins University)和美国国立卫生研究院(National Institutes of Health)的研究生培养。Seidenberg博士担任Auxogyn公司,3-V生物科学公司,呼吸技术公司和Epizyme公司,该公司全国证券交易商自动报价系统协会代码为EPZM(NASDAQ:EPZM),iPierian公司,Redbrick Health公司 和 Practice Fusion公司的董事会成员。
Beth Seidenberg has served as a member of the Board since our founding in August 2012. Dr. Seidenberg is a General Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, where she has primarily focused on life sciences investing since May 2005. Dr. Seidenberg was previously the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, Inc., a biotechnology company. In addition, Dr. Seidenberg was a senior executive in research and development at Bristol Myers Squibb Company, a biopharmaceutical company, and Merck. Dr. Seidenberg received a B.S. from Barnard College and an M.D. from the University of Miami School of Medicine and completed her post-graduate training at The Johns Hopkins University, George Washington University and the National Institutes of Health. Dr. Seidenberg serves on the board of directors of TESARO and Epizyme, Inc.
Beth Seidenberg has served as a member of the Board since our founding in August 2012. Dr. Seidenberg is a General Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, where she has primarily focused on life sciences investing since May 2005. Dr. Seidenberg was previously the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, Inc., a biotechnology company. In addition, Dr. Seidenberg was a senior executive in research and development at Bristol Myers Squibb Company, a biopharmaceutical company, and Merck. Dr. Seidenberg received a B.S. from Barnard College and an M.D. from the University of Miami School of Medicine and completed her post-graduate training at The Johns Hopkins University, George Washington University and the National Institutes of Health. Dr. Seidenberg serves on the board of directors of TESARO and Epizyme, Inc.

Beth Seidenberg自2011年6月担任公司董事会成员,自2005年5月,Seidenberg博士是凯鹏华拜耳公司(Kleiner Perkins Caufield & Byers)的合伙人,这是一家风险投资公司,在那里她主要集中于生命科学投资。Seidenberg博士曾任安进公司(Amgen, Inc)的高级副总裁兼全球发展负责人和首席医疗官,该公司在全国证券交易商自动报价系统协会代码为AMGN(NASDAQ:AMGN),是一家生物技术公司。此外,Seidenberg博士在一家生物制药公司Bristol Myers Squibb公司,该公司在纽约证券交易所代码为AMGN(NYSE:BMY)以及医疗保健公司默克制药公司(Merck & Co., Inc),该公司在纽约证券交易所代码为MRK(NYSE:MRK),任职研究和开发的高级管理人员。Seidenberg博士获迈阿密医药大学(University of Miami School of Medicine)医学士学位和巴纳德学院(Barnard College)理学学士学位,并完成了约翰·霍普金斯大学(Johns Hopkins University)和美国国立卫生研究院(National Institutes of Health)的研究生培养。Seidenberg博士担任Auxogyn公司,3-V生物科学公司,呼吸技术公司和Epizyme公司,该公司全国证券交易商自动报价系统协会代码为EPZM(NASDAQ:EPZM),iPierian公司,Redbrick Health公司 和 Practice Fusion公司的董事会成员。

James O. Armitage
James O. Armitage。自2013年5月,Armitage博士在我们的董事会任职。自2003年起,他一直是内布拉斯加大学医学中心(University of Nebraska Medical Center)内科血液学和肿瘤学的教授。自1982年加盟该中心他曾担任内科主任,药学院院长,以及其他各种职务,他还持有内布拉斯加医疗中心(The Nebraska Medical Center)和大学医院(University Hospital)的任命。Armitage博士撰写或合作撰写了超过545篇论文,100篇书刊篇章和编辑或合编教材27本。他曾担任 American Society of Clinical Oncology "ASCO" 的总裁和ASCO董事会成员。Armitage博士获内布拉斯加大学(University of Nebraska)理学学士学位和内布拉斯加大学医学中心(the University of Nebraska Medical Center)医学学位,并完成了他在内布拉斯加大学医学中心(University of Nebraska Medical Center)和爱荷华大学医院和诊所(the University of Iowa Hospitals and Clinics)的研究生培养。
James O. Armitage has served on our board of directors since May 2013. Dr. Armitage has been a professor of internal medicine in the division of hematology and oncology at the University of Nebraska Medical Center since 2003 after having served as chairman of the department of internal medicine, dean of the college of medicine, and in various other capacities since joining the Center in 1982. He also holds hospital appointments at The Nebraska Medical Center and University Hospital. Dr. Armitage has authored or co-authored more than 562 articles, 108 book chapters and edited or co-edited 27 textbooks. He has previously served as president of the American Society of Clinical Oncology ""ASCO"", and as a member of the ASCO board of directors. Dr. Armitage received a bachelor of science degree from the University of Nebraska and a medical degree from the University of Nebraska Medical Center and completed his post-graduate training at the University of Nebraska Medical Center and the University of Iowa Hospitals and Clinics.
James O. Armitage has served on our board of directors since May 2013. Dr. Armitage has been a professor of internal medicine in the division of hematology and oncology at the University of Nebraska Medical Center since 2003 after having served as chairman of the department of internal medicine, dean of the college of medicine, and in various other capacities since joining the Center in 1982. He also holds hospital appointments at The Nebraska Medical Center and University Hospital. Dr. Armitage has authored or co-authored more than 562 articles, 108 book chapters and edited or co-edited 27 textbooks. He has previously served as president of the American Society of Clinical Oncology ""ASCO"", and as a member of the ASCO board of directors. Dr. Armitage received a bachelor of science degree from the University of Nebraska and a medical degree from the University of Nebraska Medical Center and completed his post-graduate training at the University of Nebraska Medical Center and the University of Iowa Hospitals and Clinics.

James O. Armitage。自2013年5月,Armitage博士在我们的董事会任职。自2003年起,他一直是内布拉斯加大学医学中心(University of Nebraska Medical Center)内科血液学和肿瘤学的教授。自1982年加盟该中心他曾担任内科主任,药学院院长,以及其他各种职务,他还持有内布拉斯加医疗中心(The Nebraska Medical Center)和大学医院(University Hospital)的任命。Armitage博士撰写或合作撰写了超过545篇论文,100篇书刊篇章和编辑或合编教材27本。他曾担任 American Society of Clinical Oncology "ASCO" 的总裁和ASCO董事会成员。Armitage博士获内布拉斯加大学(University of Nebraska)理学学士学位和内布拉斯加大学医学中心(the University of Nebraska Medical Center)医学学位,并完成了他在内布拉斯加大学医学中心(University of Nebraska Medical Center)和爱荷华大学医院和诊所(the University of Iowa Hospitals and Clinics)的研究生培养。

Kavita Patel.
暂无中文简介
Kavita Patel. has served on our board of directors since March 2016. Dr. Patel has been a Non Resident Senior Fellow at The Brookings Institution, a premier research and thought leadership organization, since January 2011. In this role, Dr. Patel provides senior level vision and guidance for the Center for Health Policy in the Department of Economic Studies of the Institution, specifically helping healthcare systems understand how to transform their clinical environments to become more accountable for the care they provide. Dr. Patel has also been a practicing primary care physician at Johns Hopkins since January 2011. From 2009 to 2010 she served as Director of Policy for the Office on Intergovernmental Affairs and Public Engagement at The White House. Prior to that, she served as Deputy Staff Director for Health for Senator Edward M. Kennedy from 2007 to 2009. Dr. Patel currently serves as a member of the Board of Directors of SSM Healthcare, a nonprofit integrated delivery system, Community Catalyst, a national advocacy organization, and the National Initiative for Children's Healthcare Quality. She is also a member of the advisory board for the National Commission on Physician Payment Reform, the Robert Graham Center for Policy Studies in Family Medicine and Primary Care, and the Johns Hopkins Medicine Sibley Hospital Innovation Hub. Dr. Patel earned her B.A. from the University of Texas at Austin, her M.D. from the University of Texas Health Science Center, and her M.S.H.S. from the University of California, Los Angeles.
Kavita Patel. has served on our board of directors since March 2016. Dr. Patel has been a Non Resident Senior Fellow at The Brookings Institution, a premier research and thought leadership organization, since January 2011. In this role, Dr. Patel provides senior level vision and guidance for the Center for Health Policy in the Department of Economic Studies of the Institution, specifically helping healthcare systems understand how to transform their clinical environments to become more accountable for the care they provide. Dr. Patel has also been a practicing primary care physician at Johns Hopkins since January 2011. From 2009 to 2010 she served as Director of Policy for the Office on Intergovernmental Affairs and Public Engagement at The White House. Prior to that, she served as Deputy Staff Director for Health for Senator Edward M. Kennedy from 2007 to 2009. Dr. Patel currently serves as a member of the Board of Directors of SSM Healthcare, a nonprofit integrated delivery system, Community Catalyst, a national advocacy organization, and the National Initiative for Children's Healthcare Quality. She is also a member of the advisory board for the National Commission on Physician Payment Reform, the Robert Graham Center for Policy Studies in Family Medicine and Primary Care, and the Johns Hopkins Medicine Sibley Hospital Innovation Hub. Dr. Patel earned her B.A. from the University of Texas at Austin, her M.D. from the University of Texas Health Science Center, and her M.S.H.S. from the University of California, Los Angeles.

暂无中文简介

高管简历

中文 |  英文 |  中英对照
Jeffrey H. Hanke
暂无中文简介
Jeffrey H. Hanke has served as Executive Vice President, Research and Development, and Chief Scientific Officer since June 2015. Prior to joining us, Dr. Hanke was Senior Vice President, Research, and Global Head of Biotherapeutics at Boehringer Ingelheim, Inc., where he led the company's U.S. research activities and managed the biotherapeutics group, since 2010. He previously served as Vice President of Cancer Research at AstraZeneca, and in several roles of increasing responsibility within the R&D organization at Pfizer. Dr. Hanke has more than twenty-five years of experience in biopharmaceutical research and development. Dr. Hanke received his Ph.D. in immunology and microbiology from Baylor College of Medicine and his M.S. in biology from Fordham University. He completed his post-doctoral training at the University of Texas Southwestern Medical School.
Jeffrey H. Hanke has served as Executive Vice President, Research and Development, and Chief Scientific Officer since June 2015. Prior to joining us, Dr. Hanke was Senior Vice President, Research, and Global Head of Biotherapeutics at Boehringer Ingelheim, Inc., where he led the company's U.S. research activities and managed the biotherapeutics group, since 2010. He previously served as Vice President of Cancer Research at AstraZeneca, and in several roles of increasing responsibility within the R&D organization at Pfizer. Dr. Hanke has more than twenty-five years of experience in biopharmaceutical research and development. Dr. Hanke received his Ph.D. in immunology and microbiology from Baylor College of Medicine and his M.S. in biology from Fordham University. He completed his post-doctoral training at the University of Texas Southwestern Medical School.

暂无中文简介
Leon O. Moulder, Jr.
Leon O. Moulder, Jr.自2010年3月共同创办公司担任首席执行官,并成为我们的董事会成员,从2009年4月至2010年1月Moulder先生担任Abraxis生物科技公司董事会副主席、总裁兼首席执行官,这是一家生物技术公司,并担任其全资运营子公司,Abraxis生物科技有限责任公司和Abraxis公司肿瘤事业部的总裁兼首席执行官。在此之前,从2008年1月至2009年1月Moulder先生担任 Eisai北美公司的副主席,直到2008年1月被制药公司MGI PHARMA公司收购。Moulder先生从2003年5月到2008年1月担任MGI PHARMA公司总裁兼首席执行官,并且是董事会成员。Moulder先生于1999年9月加入MGI PHARMA,担任执行副总裁并于2002年5月晋升为总裁首席运营官。Moulder先生获得坦普尔大学(Temple University)药剂学学士学位和芝加哥大学(University of Chicago)工商管理硕士学位。Moulder先生目前担任Trevena公司董事会主席,该公司全国证券交易商自动报价系统协会代码为TRVN(NASDAQ: TRVN),并作为Cubist Pharmaceuticals公司的董事,该公司全国证券交易商自动报价系统协会代码为CBST(NASDAQ: CBST),这两者都是生物制药企业,并作为坦普尔大学(Temple University)的信托人。
Leon O. Moulder, Jr. has served as Chief Executive Officer and as a member of our board of directors since co-founding the Company in March 2010. From April 2009 to January 2010 Mr. Moulder served as vice chairman of the board of directors and president and chief executive officer of Abraxis BioScience, Inc., a biotechnology company. Before that, Mr. Moulder served as vice chairman of Eisai Corporation of North America, from January 2008 until January 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc., a pharmaceutical company, in January 2008. Mr. Moulder served as president and chief executive officer and as member of the board of directors of MGI PHARMA, Inc. from May 2003 through January 2008. Mr. Moulder joined MGI PHARMA, Inc. in September 1999 as executive vice president and was promoted to president and chief operating officer in May 2002. Mr. Moulder earned a bachelor of science degree in pharmacy from Temple University and a master of business administration degree from the University of Chicago. Mr. Moulder currently serves as chairman of the board of directors of Trevena, Inc. NASDAQ: TRVN, as a trustee of Temple University, and is on the board of the Fox Chase Cancer Center. Mr. Moulder also served as a director of Cubist Pharmaceuticals, Inc. through the sale of the company in 2015.
Leon O. Moulder, Jr. has served as Chief Executive Officer and as a member of our board of directors since co-founding the Company in March 2010. From April 2009 to January 2010 Mr. Moulder served as vice chairman of the board of directors and president and chief executive officer of Abraxis BioScience, Inc., a biotechnology company. Before that, Mr. Moulder served as vice chairman of Eisai Corporation of North America, from January 2008 until January 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc., a pharmaceutical company, in January 2008. Mr. Moulder served as president and chief executive officer and as member of the board of directors of MGI PHARMA, Inc. from May 2003 through January 2008. Mr. Moulder joined MGI PHARMA, Inc. in September 1999 as executive vice president and was promoted to president and chief operating officer in May 2002. Mr. Moulder earned a bachelor of science degree in pharmacy from Temple University and a master of business administration degree from the University of Chicago. Mr. Moulder currently serves as chairman of the board of directors of Trevena, Inc. NASDAQ: TRVN, as a trustee of Temple University, and is on the board of the Fox Chase Cancer Center. Mr. Moulder also served as a director of Cubist Pharmaceuticals, Inc. through the sale of the company in 2015.

Leon O. Moulder, Jr.自2010年3月共同创办公司担任首席执行官,并成为我们的董事会成员,从2009年4月至2010年1月Moulder先生担任Abraxis生物科技公司董事会副主席、总裁兼首席执行官,这是一家生物技术公司,并担任其全资运营子公司,Abraxis生物科技有限责任公司和Abraxis公司肿瘤事业部的总裁兼首席执行官。在此之前,从2008年1月至2009年1月Moulder先生担任 Eisai北美公司的副主席,直到2008年1月被制药公司MGI PHARMA公司收购。Moulder先生从2003年5月到2008年1月担任MGI PHARMA公司总裁兼首席执行官,并且是董事会成员。Moulder先生于1999年9月加入MGI PHARMA,担任执行副总裁并于2002年5月晋升为总裁首席运营官。Moulder先生获得坦普尔大学(Temple University)药剂学学士学位和芝加哥大学(University of Chicago)工商管理硕士学位。Moulder先生目前担任Trevena公司董事会主席,该公司全国证券交易商自动报价系统协会代码为TRVN(NASDAQ: TRVN),并作为Cubist Pharmaceuticals公司的董事,该公司全国证券交易商自动报价系统协会代码为CBST(NASDAQ: CBST),这两者都是生物制药企业,并作为坦普尔大学(Temple University)的信托人。

Mary Lynne Hedley
Mary Lynne Hedley自2010年3月共同创办公司担任公司总裁兼首席科学官,并是我们的董事会成员,从2009年7月至2010年2月Hedley博士担任Abraxis生物科学公司的运营部执行副总裁兼首席科学官,这是一家生物技术公司。从2008年1月至2009年7月Hedley博士担任北美卫材公司(Eisai Corporation of North America)的执行副总裁,该公司于2008年1月被MGI PHARMA公司收购。Hedley博士从2004年到2008年1月它收购Eisai,曾在MGI PHARMA不同的岗位任职,最近担任执行副总裁兼首席科学官。在此之前,Hedley博士于2004年共同创办Zycos,博士担任ZYCOS公司的总裁兼首席执行官,是一家生物技术公司,该公司被MGI制药公司收购。Hedley获得哈佛大学(Harvard University)两个连续的博士后奖学金。Hedley博士获得普渡大学(Purdue University)微生物学士学位和德克萨斯大学西南医学中心(the University of Texas, Southwestern Medical Center)免疫博士学位。
Mary Lynne Hedley has served as our President and as a member of our board of directors since co-founding the Company in March 2010. She also served in the role of Chief Scientific Officer from the Company's founding until the board of directors appointed her to the role of Chief Operating Officer effective July 24 2014. From July 2009 to February 2010 Dr. Hedley served as executive vice president of operations and chief scientific officer of Abraxis BioScience, Inc., a biotechnology company. Dr. Hedley served as executive vice president of Eisai Corporation of North America from January 2008 until July 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc. in January 2008. Dr. Hedley served in various positions at MGI PHARMA, Inc. from 2004 through its acquisition in January 2008 most recently as executive vice president and chief scientific officer. Prior to that, Dr. Hedley co-founded and served as the president and chief executive officer of ZYCOS, Inc., a biotechnology company, which was acquired by MGI PHARMA, Inc. in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University. Dr. Hedley earned a bachelor of science degree in microbiology from Purdue University and degree in immunology from the University of Texas, Southwestern Medical Center. Dr. Hedley currently serves as a director of Youville Place, Inc. She also served on the board of Receptos, Inc. prior to its acquisition by Celgene Corp. in August 2015.
Mary Lynne Hedley has served as our President and as a member of our board of directors since co-founding the Company in March 2010. She also served in the role of Chief Scientific Officer from the Company's founding until the board of directors appointed her to the role of Chief Operating Officer effective July 24 2014. From July 2009 to February 2010 Dr. Hedley served as executive vice president of operations and chief scientific officer of Abraxis BioScience, Inc., a biotechnology company. Dr. Hedley served as executive vice president of Eisai Corporation of North America from January 2008 until July 2009 following Eisai Co. Ltd.'s acquisition of MGI PHARMA, Inc. in January 2008. Dr. Hedley served in various positions at MGI PHARMA, Inc. from 2004 through its acquisition in January 2008 most recently as executive vice president and chief scientific officer. Prior to that, Dr. Hedley co-founded and served as the president and chief executive officer of ZYCOS, Inc., a biotechnology company, which was acquired by MGI PHARMA, Inc. in 2004. Prior to co-founding Zycos, Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard University. Dr. Hedley earned a bachelor of science degree in microbiology from Purdue University and degree in immunology from the University of Texas, Southwestern Medical Center. Dr. Hedley currently serves as a director of Youville Place, Inc. She also served on the board of Receptos, Inc. prior to its acquisition by Celgene Corp. in August 2015.

Mary Lynne Hedley自2010年3月共同创办公司担任公司总裁兼首席科学官,并是我们的董事会成员,从2009年7月至2010年2月Hedley博士担任Abraxis生物科学公司的运营部执行副总裁兼首席科学官,这是一家生物技术公司。从2008年1月至2009年7月Hedley博士担任北美卫材公司(Eisai Corporation of North America)的执行副总裁,该公司于2008年1月被MGI PHARMA公司收购。Hedley博士从2004年到2008年1月它收购Eisai,曾在MGI PHARMA不同的岗位任职,最近担任执行副总裁兼首席科学官。在此之前,Hedley博士于2004年共同创办Zycos,博士担任ZYCOS公司的总裁兼首席执行官,是一家生物技术公司,该公司被MGI制药公司收购。Hedley获得哈佛大学(Harvard University)两个连续的博士后奖学金。Hedley博士获得普渡大学(Purdue University)微生物学士学位和德克萨斯大学西南医学中心(the University of Texas, Southwestern Medical Center)免疫博士学位。

Grant C. Bogle
暂无中文简介
Grant C. Bogle has served as Senior Vice President and Chief Commercial Officer since July 2015. Prior to joining us, Mr. Bogle was Senior Vice President, Pharmaceutical and Biotech Solutions at McKesson Specialty Health, where he was part of the executive leadership team and led the informatics, health economics and outcomes research, reimbursement access and safety services, and U.S. Oncology Clinical Research business units. These business units were comprised of approximately 1000 employees. Mr. Bogle was an employee of McKesson for eight years prior to joining us. Previously, he was Senior Vice President of Sales and Marketing for Millennium Pharmaceuticals, where he was responsible for the oncology product, VELCADE. Prior to joining Millennium, Mr. Bogle held senior sales and marketing roles at numerous other pharmaceutical companies. He holds an M.B.A. from Columbia University and a B.A. in economics from Dartmouth College.
Grant C. Bogle has served as Senior Vice President and Chief Commercial Officer since July 2015. Prior to joining us, Mr. Bogle was Senior Vice President, Pharmaceutical and Biotech Solutions at McKesson Specialty Health, where he was part of the executive leadership team and led the informatics, health economics and outcomes research, reimbursement access and safety services, and U.S. Oncology Clinical Research business units. These business units were comprised of approximately 1000 employees. Mr. Bogle was an employee of McKesson for eight years prior to joining us. Previously, he was Senior Vice President of Sales and Marketing for Millennium Pharmaceuticals, where he was responsible for the oncology product, VELCADE. Prior to joining Millennium, Mr. Bogle held senior sales and marketing roles at numerous other pharmaceutical companies. He holds an M.B.A. from Columbia University and a B.A. in economics from Dartmouth College.

暂无中文简介
Timothy R. Pearson
Timothy R. Pearson自2014年3月起担任公司董事。Pearson自2014年5月起担任TESARO, Inc.(一家专注于肿瘤学的生物制药公司)首席财务官。他还从2011年8月起担任Catalyst Health Solutions(一家制药利益管理公司)执行副总裁和首席财务官,一直担任到2012年7月该公司被SXC Health Solutions收购。加入Catalyst Health Solutions之前,Pearson从2007年到2011年担任MedImmune(AstraZeneca PLC一家全球生物企业)首席财务官和执行副总裁;他也是MedImmune执行小组成员。Pearson于1998年加入MedImmune,2007年被提升为首席财务官,在此之前一直担任金融副总裁和财务主管。Pearson还曾担任MedImmune Ventures(MedImmune的风险资本基金,对初期生物技术公司进行投资)创始人和投资委员会成员。Pearson是一名注册会计师,持有the University of Delaware工商管理和the University of Maryland, University College会计双学位;Loyola University金融硕士学位。
Timothy R. Pearson has served as a member of our board of directors since May 2016. Mr. Pearson currently serves as Chief Financial Officer of TESARO, Inc., an oncology-focused biopharmaceutical company, where he has served since May 2014. Prior to joining TESARO, Mr. Pearson served as Executive Vice President and Chief Financial Officer of Catalyst Health Solutions, Inc. from August 2011 to July 2012 where he led the finance and strategic planning functions. Mr. Pearson holds a B.S. in Business Administration from the University of Delaware, an M.S. in Finance from Loyola College and a B.S. in Accounting from the University of Maryland University College. He is also a Certified Public Accountant.
Timothy R. Pearson has served as a member of our board of directors since May 2016. Mr. Pearson currently serves as Chief Financial Officer of TESARO, Inc., an oncology-focused biopharmaceutical company, where he has served since May 2014. Prior to joining TESARO, Mr. Pearson served as Executive Vice President and Chief Financial Officer of Catalyst Health Solutions, Inc. from August 2011 to July 2012 where he led the finance and strategic planning functions. Mr. Pearson holds a B.S. in Business Administration from the University of Delaware, an M.S. in Finance from Loyola College and a B.S. in Accounting from the University of Maryland University College. He is also a Certified Public Accountant.

Timothy R. Pearson自2014年3月起担任公司董事。Pearson自2014年5月起担任TESARO, Inc.(一家专注于肿瘤学的生物制药公司)首席财务官。他还从2011年8月起担任Catalyst Health Solutions(一家制药利益管理公司)执行副总裁和首席财务官,一直担任到2012年7月该公司被SXC Health Solutions收购。加入Catalyst Health Solutions之前,Pearson从2007年到2011年担任MedImmune(AstraZeneca PLC一家全球生物企业)首席财务官和执行副总裁;他也是MedImmune执行小组成员。Pearson于1998年加入MedImmune,2007年被提升为首席财务官,在此之前一直担任金融副总裁和财务主管。Pearson还曾担任MedImmune Ventures(MedImmune的风险资本基金,对初期生物技术公司进行投资)创始人和投资委员会成员。Pearson是一名注册会计师,持有the University of Delaware工商管理和the University of Maryland, University College会计双学位;Loyola University金融硕士学位。

Joseph L. Farmer
Joseph L. Farmer,2005年2月成为我们总法律顾问和法律事务副总裁。Farmer先生2008年5月晋升为法律事务高级副总裁,2011年12月成为首席行政官,自2007年他还曾担任我们的秘书长,在加入我们之前,从1997年到2005年Farmer先生是波士顿Testa, Hurwitz和Thibeault有限责任公司(Thibeault, LLP)律师事务所商务实践部的律师,Farmer先生目前担任波士顿管家卡尼医院(Steward Carney Hospital)托管理事会和病人护理咨询委员会成员。他获得波士顿大学(Boston University)经济学学士学位以及波士顿大学法学院(Boston College Law School)法学博士学位。
Joseph L. Farmer has served as Senior Vice President, General Counsel and Secretary since March 2015. From November 2012 until February 2015 Mr. Farmer served as Vice President, Chief Corporate Counsel and Assistant Secretary of Cubist Pharmaceuticals, Inc., prior to its sale to Merck & Co., Inc. Prior to joining Cubist, Mr. Farmer served as Vice President, General Counsel and Secretary of publicly-traded software company Pegasystems Inc. from June until November 2012. From February 2005 until June 2012 Mr. Farmer held management positions with increasing levels of responsibility at AMAG Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company, including as its Chief Administrative Officer, General Counsel and Secretary. He received his B.A. in economics from Boston University and his J.D. from Boston College Law School.
Joseph L. Farmer has served as Senior Vice President, General Counsel and Secretary since March 2015. From November 2012 until February 2015 Mr. Farmer served as Vice President, Chief Corporate Counsel and Assistant Secretary of Cubist Pharmaceuticals, Inc., prior to its sale to Merck & Co., Inc. Prior to joining Cubist, Mr. Farmer served as Vice President, General Counsel and Secretary of publicly-traded software company Pegasystems Inc. from June until November 2012. From February 2005 until June 2012 Mr. Farmer held management positions with increasing levels of responsibility at AMAG Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company, including as its Chief Administrative Officer, General Counsel and Secretary. He received his B.A. in economics from Boston University and his J.D. from Boston College Law School.

Joseph L. Farmer,2005年2月成为我们总法律顾问和法律事务副总裁。Farmer先生2008年5月晋升为法律事务高级副总裁,2011年12月成为首席行政官,自2007年他还曾担任我们的秘书长,在加入我们之前,从1997年到2005年Farmer先生是波士顿Testa, Hurwitz和Thibeault有限责任公司(Thibeault, LLP)律师事务所商务实践部的律师,Farmer先生目前担任波士顿管家卡尼医院(Steward Carney Hospital)托管理事会和病人护理咨询委员会成员。他获得波士顿大学(Boston University)经济学学士学位以及波士顿大学法学院(Boston College Law School)法学博士学位。

Martin H. Huber
暂无中文简介
Martin H. Huber has served as Senior Vice President and Chief Medical Officer since September 2015. Prior to joining the Company, beginning in 2009 Dr. Huber served as Vice President, Oncology Clinical Research, at Merck Research Laboratories. Dr. Huber has over 20 years of leadership experience in the biopharmaceutical industry. Prior to Merck, he served in roles of increasing responsibility at Schering-Plough, Hoffmann-La Roche and Rhone-Poulenc Rorer, where he led teams in the areas of oncology clinical development, drug safety and pharmacovigilance. He previously served as an assistant professor of oncology at the University of Texas MD Anderson Cancer Center. Dr. Huber received his M.D. from Baylor College of Medicine.
Martin H. Huber has served as Senior Vice President and Chief Medical Officer since September 2015. Prior to joining the Company, beginning in 2009 Dr. Huber served as Vice President, Oncology Clinical Research, at Merck Research Laboratories. Dr. Huber has over 20 years of leadership experience in the biopharmaceutical industry. Prior to Merck, he served in roles of increasing responsibility at Schering-Plough, Hoffmann-La Roche and Rhone-Poulenc Rorer, where he led teams in the areas of oncology clinical development, drug safety and pharmacovigilance. He previously served as an assistant professor of oncology at the University of Texas MD Anderson Cancer Center. Dr. Huber received his M.D. from Baylor College of Medicine.

暂无中文简介